CommercialCoverageMedium impact
Chimeric Antigen Receptor Therapy for Leukemia and Lymphoma
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for CAR-T cell therapy treatments for leukemia and lymphoma. This policy covers five FDA-approved CAR-T therapies (Aucatzyl, Breyanzi, Kymriah, Tecartus, Yescarta) and provides detailed coverage criteria for specific blood cancer conditions including B-cell ALL, diffuse large B-cell lymphoma, and mantle cell lymphoma.
Action Required
Review updated CAR-T therapy policy A.8.01.63 to understand coverage criteria for the five approved therapies (Aucatzyl, Breyanzi, Kymriah, Tecartus, Yescarta). Oncology and hematology teams should ensure documentation supports medical necessity for these high-cost treatments and verify patient eligibility criteria before treatment initiation.